Please login to the form below

Not currently logged in
Email:
Password:

biologics

This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

clutch of new biologic therapies elbowing for market share in the increasingly crowded psoriasis category.

Latest news

More from news
Approximately 18 fully matching, plus 499 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... The third area is immuno-oncology (IO)

  • Deal Watch October 2018

    non‐biologic product post‐patent loss, highlighting the benefits of biologics in the long term and the complexities of developing and manufacturing them. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination. $155m.

  • Nudge-nudge, think-think Nudge-nudge, think-think

    The power of achieving the triad of capability, opportunity and peer endorsement is evidenced by a recent study into how to avoid retrograde outcomes when switching patients from biologics to biosimilars.

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    and biologics housed under the same roof. ... Co-locating scientists who work on chemistry and small molecule drug development with scientists who work on biologics, large molecules and protein based therapeutics, in lab-based environments for the first

More from intelligence
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 45 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 7 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics